Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on April 16, 2009

Arteriosclerosis, Thrombosis, and Vascular Biology. 2009
Published online before print April 16, 2009, doi: 10.1161/ATVBAHA.109.187567
A more recent version of this article appeared on July 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/7/1138    most recent
ATVBAHA.109.187567v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schneider, D. J.
Right arrow Articles by Taatjes-Sommer, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schneider, D. J.
Right arrow Articles by Taatjes-Sommer, H. S.

Submitted on December 18, 2008
Accepted on April 7, 2009

Augmentation of Megakaryocyte Expression of Fc{gamma}RIIa by Interferon {gamma}

David J. Schneider * and Heidi S. Taatjes-Sommer

From the Cardiology Unit, and Cardiovascular Research Institute, Department of Medicine, University of Vermont, Burlington.

* To whom correspondence should be addressed. E-mail: david.schneider{at}uvm.edu.

Objective—The purpose of this study was to identify factors that alter expression of Fc{gamma}RIIa by megakaryocytes.

Methods and Results—Effects of selected cytokines and growth factors on megakaryocyte expression of Fc{gamma}RIIa were assessed with phorbol 12-myristate 13-acetate (PMA)-differentiated human erythroleukemia (HEL) cells and with thrombopoietin-differentiated CD34 stem cells and compared with those obtained with myelocytic cell lines and a monocytic cell lines. Expression of Fc{gamma}RIIa was quantified with the use of Western blots and real-time reverse transcriptase–polymerase chain reaction. Megakaryocyte differentiation was identified by expression of CD41, CD42, and von Willebrand factor with the use of flow cytometry. Interferon (IFN) {gamma} increased protein expression of Fc{gamma}RIIa by HEL cells and CD34 stem cells after megakaryocyte differentiation (maximal {approx}4-fold, P<0.001 for each). IFN{gamma} did not increase expression of Fc{gamma}RIIa by undifferentiated HEL and CD34 cells. Expression of Fc{gamma}RIIa mRNA was increased (2-fold, P<0.001) in megakaryocyte-differentiated HEL cells. IFN{gamma} did not increase expression of Fc{gamma}RIIa by undifferentiated myelocytic or monocytic cell lines.

Conclusions—IFN{gamma} appears to selectively increase expression of Fc{gamma}RIIa by cells exhibiting characteristics of megakaryocytes. This effect of IFN{gamma} may contribute to greater platelet expression of Fc{gamma}RIIa in patients with atherosclerotic vascular disease.
Key words: atherosclerosis • Fc{gamma}R • inflammation • platelets • megakaryocytes






ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.